Multiple Myeloma Market Size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017-2030)

The Multiple Myeloma Market report provides emerging drugs, Multiple Myeloma market share of the individual cancer types, current and forecasted Multiple Myeloma market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Multiple Myeloma unmet medical needs to curate best of the opportunities and assesses underlying potential of the market

Key takeaways from the Multiple Myeloma Market Research Report
• In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2030. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
• The overall number of symptomatic cases of Multiple Myeloma in the 8MM was 80,715, and these cases are expected to rise by 2030.
• Males are more likely to develop Multiple Myeloma than females (about 55 percent of cases). When it comes to age-specific Multiple Myeloma cases, the age group 65-74 years has by far the most, followed by 75-84 years and 55-64 years.
• In the 8MM, the total cases of Multiple Myeloma by treatment line were 23,581 cases for frontline transplant-eligible patients, 49,699 cases for frontline transplant-ineligible patients, 44,955 cases for second-line patients, 23,498 cases for third-line patients, and 10,236 cases for fourth-line plus patients, in the year 2020.
• The leading Multiple Myeloma Companies include GlaxoSmithKline, Bristol-Myers Squibb/Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical (Millennium Pharmaceuticals), Sanofi, Karyopharm Therapeutics, Janssen Biotech, Bristol Myers Squibb/AbbVie, Takeda Pharmaceutical/Janssen Pharmaceutical,Celgene (BMS), and others.
• Promising Multiple Myeloma Pipeline Therapies in various stages of development include belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Elotuzumab, Bortezomib, BT062, Pomalidomide, Tocilizumab, Cevostamab, cyclophosphamide, and others.

To explore more information on the latest breakthroughs in the Multiple Myeloma Treatment Landscape, visit Multiple Myeloma Market Size @ https://www.delveinsight.com/sample-request/multiple-myeloma-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Multiple Myeloma Treatment Landscape
• In June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the USFDA has granted Breakthrough Therapy Designation for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, a bispecific antibody targeting both BCMA and CD3 receptors, follows a PRIME designation from the EMA received earlier this year.
• In May 2021, Oncopeptides has announced positive results from the OCEAN study, which compared the effectiveness and safety of melflufen with pomalidomide in patients with relapsed refractory multiple myeloma. The phase III OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
• In May 2021, the USFDA granted priority review to the Biologics License Applications (BLA) for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma. The regulatory agency is expected to decide on the application by November 29, 2021, under the Prescription Drug User Fee Act.
• In April 2021, Legend Biotech announced the submission of a MAA to the EMA seeking approval of ciltacabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma. The EMA's Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment for this MAA.

Multiple Myeloma Overview
Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females.

Multiple myeloma Epidemiology Segmentation in the 7MM
• Total Multiple Myeloma Incidence
• Total Multiple Myeloma Symptomatic Cases
• Total Multiple Myeloma Incident Cases of Segmented by Gender
• Total Multiple Myeloma Diagnosed cases by Age Distribution
• Total Multiple Myeloma Cases by Line of Treatment

Find new updates of the Multiple Myeloma Market Trends of the report, click here Multiple Myeloma Market Forecast @ https://www.delveinsight.com/sample-request/multiple-myeloma-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Marketed Drugs

Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline
GlaxoSmithKline's lead candidate, Belantamab Mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with an afucosylated, humanized IgG1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa. It was approved by UDFDA and the European Commission in August 2020. This drug has received orphan drug designation from the EMA and the US FDA for multiple myeloma. Apart from this, the EMA and the US FDA have also granted PRIME designation and Breakthrough Therapy designation, respectively.

Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
Abecma (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy co-developed, and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. In March 2021, the USFDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.

Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB
Pepaxto is a first-in-class anti-cancer peptide-drug conjugate that rapidly produces an alkylating payload into tumor cells. It is promptly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In February 2021, the USFDA approved Pepaxto in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

Sarclisa (Isatuximab): Sanofi
Sarclisa- a product of Sanofi is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is manufactured and designed to initiate programmed tumor cell death (apoptosis) and immunomodulatory activity. In December 2017, Isatuximab received Orphan Designation for the treatment of patients with Relapsed or Refractory Multiple Myeloma by the US FDA and EMA.

Xpovio (Selinexor): Karyopharm
Karyopharm' potential candidate Selinexor is an oral, first-in-class, selective inhibitor of nuclear export also known as SINE, compound. It has been approved by the US FDA in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In April 2021, EMA validated the Company's Type II Variation MAA, which seeks to expand the currently authorized indication for Nexpovio in the European Union to include, in combination with Velcade (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA's review process.

Darzalex (Daratumumab): Janssen Biotech
Darzalex (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. Darzalex is not chemotherapy. It is a human IgG1k monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. In November 2015, Darzalex first received the US FDA approval as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. Recently, in April 2020, the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.

Multiple Myeloma Emerging Drugs

Venetoclax (ABT-199): AbbVie and Roche
Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. It is used for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) and in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. In March 2019, the US FDA placed a partial clinical hold on Venetoclax's multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase III trial (NCT02755597). In June 2019, the US FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol (Myeloma Positive for the t(11;14) Genetic Abnormality), including new risk mitigation measures, protocol-specified guidelines, and updated futility criteria (AbbVie News Center, 2019).

Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech
Ciltacabtagene Autoleucel is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an immunomodulatory drug and a proteasome inhibitor. This product is being evaluated under licensing and collaboration agreements between Janssen and Legend Biotech. In the first quarter of 2021, the rolling submission of a Biologics License Application (BLA) to the USFDA was completed by Janssen, for cilta-cel, for the treatment of adults with relapsed or refractory multiple myeloma. Additionally, in April 2021, the company has also submitted the MAA to the EMA for cilta-cel (Legend Biotech, 2021b).

REGN5458: Regeneron Pharmaceuticals
REGN5458 is a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. In December 2019, the company presented the results at the American Society of Hematology (ASH) Annual Meeting. Currently, REGN5458 monotherapy is being investigated in an open-label, Phase I/II (NCT03761108) dose-escalation trial in patients with relapsed or refractory multiple myeloma who are at least triple refractory to existing therapeutic options, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibody treatments.

Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
Iberdomide is an investigational cereblon E3 ligase modulator compound with enhanced tumoricidal and Immunostimulatory activities that induces degradation of transcription factors Aiolos and Ikaros, thereby inhibiting the growth of myeloma cells in vitro. In pre-clinical models, iberdomide has demonstrated the ability to destroy tumor cells, stimulate an immune response, overcome resistance to immunomodulatory drugs, and synergize with dexamethasone, daratumumab, and bortezomib (Celgene Corporation, 2019). In December 2018, the US FDA has granted orphan drug designation to iberdomide for the treatment of multiple myeloma.

Get to know more about the Multiple Myeloma Recent News, Updates of the Multiple Myeloma market report, click here Multiple Myeloma Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/report-store/multiple-myeloma-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Pipeline Therapies and Companies
• Venetoclax (ABT-199): AbbVie and Roche
• JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
• Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
• Cetrelimab (JNJ-63723283): Janssen Research & Development
• REGN5458: Regeneron Pharmaceuticals
• Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
• Chidamide (Epidaza): Chipscreen Biosciences
• Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
• Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
• Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
• CLR 131 (131-CLR1404): Cellectar Biosciences
• BL-8040: BioLineRx
• GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
• ECT-001: ExCellThera
• TAK-079: Takeda
• GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
• P-BCMA-101 CAR-T cells: Poseida Therapeutics
• Opdivo (Nivolumab): Bristol-Myers Squibb
• PBCAR269A: Precision BioSciences
• MP0250: Molecular Partners AG
• Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
• Descartes-11: Cartesian Therapeutics
• Imfinzi (Durvalumab): AstraZeneca
• Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson

Multiple Myeloma Market Outlook
According to DelveInsight, the Multiple Myeloma market size in the 8MM is expected to change at a CAGR of 4.3% during the study period (2017-2030). In the total market size of Multiple Myeloma in the 8MM, the United States accounted for the highest market size in 2020 followed by Japan, Germany, and France.

Discover more information on the Multiple Myeloma Market Dynamics. Click here Multiple Myeloma Market Drivers and Barriers @ https://www.delveinsight.com/report-store/multiple-myeloma-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Multiple Myeloma Market Research Report
• Coverage- United States, EU5 Japan, China
• Multiple Myeloma Companies- GlaxoSmithKline, Bristol-Myers Squibb/Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical (Millennium Pharmaceuticals), Sanofi, Karyopharm Therapeutics, Janssen Biotech, Bristol Myers Squibb/AbbVie, Takeda Pharmaceutical/Janssen Pharmaceutical,Celgene (BMS), and others.
• Multiple Myeloma Pipeline Therapies in various stages of development include belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Elotuzumab, Bortezomib, BT062, Pomalidomide, Tocilizumab, Cevostamab, cyclophosphamide, and others.
• Multiple Myeloma Market Dynamics: Multiple Myeloma Market Drivers and Barriers

Table of Content
1. Key Insights
2. Multiple Myeloma Report Introduction
3. Multiple Myeloma Market Overview at a Glance
4. Executive Summary of Multiple Myeloma
4.1. Key Events
5. Epidemiology and Market Forecast Flow
6. Disease Background and Overview
7. Diagnosis of Multiple Myeloma
8. Multiple Myeloma Treatment
9. Multiple Myeloma Epidemiology and Patient Population
10. Patient Journey
11. Key Endpoints in Multiple Myeloma
12. Multiple Myeloma Marketed Therapies
13. Multiple Myeloma Emerging Therapies
14. Multiple Myeloma: Eight Major Market Analysis
15. Multiple Myeloma Market Access and Reimbursement
16. Multiple Myeloma Market Drivers
17. Multiple Myeloma Market Barriers
18. SWOT Analysis
19. Multiple Myeloma Unmet Needs
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get to know more information of the Multiple Myeloma Market Unmet Needs, Multiple Myeloma Market Drivers, Multiple Myeloma Market Barriers, Multiple Myeloma Emerging Therapies @ https://www.delveinsight.com/report-store/multiple-myeloma-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.